Kidney Week 2021 tackled everything from kidney transplants to systemic inequities. Here to share his insight on the latest updates is Dr. John Friedewald, Professor of Medicine and Surgery at the Northwestern University Feinberg School of Medicine.

What does the future of rheumatology look like around the globe? Here to give a quick overview of her presentation at the 2021 American College of Rheumatology (ACR) Convergence is Dr. Laura Cappelli, Assistant Professor of Medicine at the Johns Hopkins University School of Medicine Division of Rheumatology and a faculty member of the Johns Hopkins Arthritis Center.

Both UNICEF and WHO recommend exclusive breastfeeding for the first six months of life, starting within the very first hour of birth. But are we adhering to that recommendation? Joining Dr. Hector Chapa to discuss the importance of breastfeeding shortly after delivery and how we can help our patients and their newborns reap the benefits of this golden hour is Dr. Susan Crowe, Director of Outpatient Breastfeeding Medicine Consultative Services at Stanford Children's Health who recently spoke about this topic at the 2021 ACOG Annual Clinical and Scientific Meeting.

ACOG's Annual Clinical and Scientific Meeting will be held virtually this year, but that doesn't mean the content is any less collaborative and impactful. Listen in to hear what ReachMD's host and practicing OB-GYN, Dr. Hector Chapa, is looking forward to at this year's meeting.

Though cannabidiol (CBD) has long been recognized in the oncological field as a palliative therapeutic agent, only recently has it been demonstrated to induce anti-tumor responses in breast cancer. To learn more, Dr. Matt Birnholz is joined by Dr. Luka Dobovisek, whose recent study looked at the effect of CBD on cell viability of selected breast cancer cell lines, both as a single agent and in combinations with breast cancer therapies such as tamoxifen.

Despite the increasing number of elderly patients diagnosed with breast cancer, few clinical trials focus on this age group. That’s why Dr. Slavica Janeva's team focused on the impacts of adjuvant chemotherapy on survival rates in this patient population, the results of which may change clinical practice paradigms moving forward, as he discusses with Dr. Matt Birnholz.

After doing breast cancer research for over 40 years, Dr. Kent Osborne has seen a lot of advances in the field, and now he’s here to share his viewpoint on the opportunities and challenges that lie ahead.

To learn more about the effects of dietary interventions after early breast cancer treatment and the current gaps that exist in systemic reviews that assess those effects, Dr. Matt Birnholz sat down with Dr. Daniela Rosa at the 2019 San Antonio Breast Cancer Symposium.

Ms. Marina Kaplan's inspiring life history as an "outlier survivor" as she put it for having achieved remission from triple-negative breast cancer over six years ago was helped by numerous cutting-edge clinical trials made accessible to her. But the experience as a study subject exposed her to systemic barriers confronting breast cancer patients everywhere, compelling her to reprise her epidemiology career expertise in conducting a study looking for novel solutions, as she shares with Dr. Matt Birnholz at the 2019 San Antonio Breast Cancer Symposium.

Recorded live at the 2019 San Antonio Breast Cancer Symposium, Dr. Matt Birnholz sat down with Dr. Nadine Tung, Associate Professor of Medicine at Harvard Medical School and Director of the Cancer Risk and Prevention Program at Beth Israel Deaconess Medical Center, to talk about her presentation on genetic testing for hereditary breast cancer.